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In the uterus insulin-like growth factor-1 (IGF-1) signal-
ing can be initiated by estradiol acting through its nu-
clear receptor (estrogen receptor (ER)) to stimulate the
local synthesis of IGF-1. Conversely, in vitro studies have
demonstrated that estradiol-independent ER transcrip-
tional activity can be induced by IGF-1 signaling, provid-
ing evidence for a cross-talk mechanism between IGF-1
and ER. To investigate whether ER is required for uter-
ine responses to IGF-1 in vivo, both wild-type (WT) and
ER knockout (ERKO) mice were administered IGF-1,
and various uterine responses to IGF-1 were compared. In
both WT and ERKO mice, IGF-1 treatment resulted in
phosphorylation of uterine IGF-1 receptor (IGF-1R) and
formation of an IGF-1R/insulin receptor substrate-1/
phosphatidylinositol 3-kinase signaling complex. In addi-
tion, IGF-1 stimulated phosphorylation of uterine Akt and
MAPK in both WT and ERKO mice. However, IGF-1
treatment stimulated BrdUrd incorporation and prolifer-
ating cell nuclear antigen expression in WT uteri only. To
determine whether ER can be activated in vivo by IGF-1
signaling, transgenic mice carrying a luciferase gene
driven by two estrogen response elements (ERE-lucifer-
ase mice) were utilized. Treatment of ovariectomized
ERE-luciferase mice with IGF-1 resulted in an increase in
uterine luciferase activity that was attenuated in the
presence of the ER antagonist ICI 182,780. Together these
data demonstrate that 1) functional signaling proximal to
IGF-1R is maintained in the ERKO mouse uterus, 2) ER
is necessary for IGF-1 induction of uterine nuclear prolif-
erative responses, and 3) cross-talk between IGF-1R and
ER signaling pathways exists in vivo.
Epithelial cells of the mammalian uterus undergo a wave of
DNA synthesis followed by mitosis in response to 17-estradiol
(E2),
1 which regulates the transcription of numerous target
genes by binding to and activating the nuclear estrogen recep-
tor (ER). Among the genes identified as targets for regulation
by the E2/ER complex in the uterus is that encoding insulin-
like growth factor-1 (IGF-1). Studies have demonstrated that
rodent uterine IGF-1 mRNA levels increase after exposure to
E2 (1, 2). Furthermore, presumably through increasing local
production of IGF-1, E2 has been shown to stimulate uterine
IGF-1 receptor (IGF-1R) signaling as measured by tyrosine
phosphorylation of IGF-1R and the formation of a signaling
complex composed of IGF-1R, insulin receptor substrate-1
(IRS-1), and p85, the regulatory subunit of phosphatidylinosi-
tol 3-kinase (PI 3-kinase) (3, 4). These studies suggested that
IGF-1 signaling is involved in E2-induced uterine growth, and
in support of this mechanism, other studies have shown that,
like E2, IGF-1 can induce DNA synthesis in cells of the rodent
uterus (5). A more recent study further demonstrated a role for
IGF-1 in E2-induced uterine proliferation by demonstrating
that IGF-1 is required for E2-induced uterine epithelial cell
mitosis (6). In that study, DNA synthesis occurred in IGF-1
knockout (IGF-1KO) mouse uteri in response to E2. However,
there was a significant decrease in the E2-stimulated mitotic
index in the uterine epithelium, indicating that IGF-1 is nec-
essary for the cells to progress properly through mitosis in
response to E2. Finally, a recent study by this laboratory has
confirmed that increased synthesis of uterine IGF-1 mRNA and
stimulation of uterine IGF-1R signaling by E2 are ER-depend-
ent events (7). Collectively, these studies have illustrated that
E2, by acting through ER, stimulates IGF-1/IGF-1R signaling
and increases uterine epithelial cell mitosis in the mouse
uterus.
Conversely related in vitro studies have described another
level of integration between the ER and IGF-1 signaling path-
ways by demonstrating that ER-mediated responses can be
induced or increased by IGF-1. An initial study showed that, in
the absence of E2, IGF-1 can stimulate the phosphorylation of
ER and induce the expression of an estrogen-responsive, ERE-
containing reporter construct, an effect that was blocked by
antiestrogen (8). Subsequent studies confirmed these findings
and further showed that IGF-1 activation of the ERE-reporter
construct occurred only in the presence of ER, demonstrating
that IGF-1 was indeed inducing reporter gene transcription
through activation of ER (9). More recently, the mechanism
through which IGF-1 activates ER was investigated, and it was
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determined that IGF-1 activation of ER is mediated, at least in
part, through a mechanism involving Akt (10). Thus, a model
develops in which it appears that E2, acting through its nuclear
receptor, initiates responses that include the induction of
IGF-1. The IGF-1, in turn, interacts with its cognate membrane
receptor to initiate a signaling cascade that involves phospho-
rylation-dependent kinases, such as Akt. The membrane recep-
tor-mediated IGF-1 signaling pathway further appears to be
linked to the ER pathway via a cross-talk mechanism
whereby activation of the IGF-1R can stimulate “ligand-inde-
pendent” ER-mediated responses.
Recently, the ERE-luciferase mouse was described as an
innovative model system for profiling the in vivo dynamics of
ER activity (11). This mouse has been engineered to carry a
luciferase transgene that is driven by two EREs from the vitel-
logenin promoter upstream of a minimal thymidine kinase
promoter. As a result, the luciferase gene is expressed only in
response to transcriptionally active ER. In an effort to further
understand the cross-talk between the IGF-1/IGF-1R and E2/
ER signaling pathways, the current study was designed to
evaluate the in vivo role of ER in IGF-1-mediated uterine
responses. By utilizing both the ER knockout (ERKO) and
ERE-luciferase mouse models, we establish the requirement
for ER in IGF-1-induced uterine nuclear responses and pro-
vide in vivo molecular evidence demonstrating the existence of
cross-talk between the uterine IGF-1 and ER signaling
pathways.
EXPERIMENTAL PROCEDURES
Materials—17-Estradiol was purchased from Steraloids (Newport,
RI). Long R3 IGF-1, a biologically active IGF-1 derivative with low
affinity for IGF-1-binding proteins, was obtained from Diagnostic Sys-
tems Laboratories (Webster, TX). The following antibodies were pur-
chased: IGF-1R (Santa Cruz Biotechnology, Santa Cruz, CA); anti-
phosphotyrosine (PY20, ICN Biomedicals, Inc., Aurora, OH); anti-IRS-1
and anti-p85 (Upstate Biotechnology, Lake Placid, NY); Akt, phospho
Akt, p42/44 MAPK, and phospho p42/44 MAPK (Cell Signaling Tech-
nology, Beverly, MA); PCNA 19A2 (Beckman Coulter, Hialeah, FL),
biotinylated anti-mouse IgM (Vector Laboratories, Inc., Burlingame,
CA); BrdUrd (Accurate Chemical and Scientific Corp., Westbury, NY).
Animals—All animals were handled in accordance with an approved
NIEHS, National Institutes of Health animal study protocol. Adult
female WT, ERKO, and ERE-luciferase mice were ovariectomized,
held for 10–14 days to clear endogenous ovarian hormones, and then
used in studies. Animals were either injected intraperitoneally with 20
g/kg estradiol (E2) in saline, or a mini-osmotic pump (Alza Corpora-
tion, Palo Alto, CA; 3 days, 1 l/h) containing 100 l of 2.4 g/l-long R3
IGF-1 dissolved in 0.1 M acetic acid was implanted in the peritoneal
cavity. Control animals were injected with saline. For BrdUrd incorpo-
ration and PCNA immunohistochemistry, mice were injected with Br-
dUrd (1 mg/mouse) 16 h after E2 or IGF-1 treatments, and uteri were
collected 1 h later. A segment of each uterine horn was frozen for
Western analysis, and the rest of the uterine tissue, as well as a piece
of the intestine, was fixed in 10% cold formalin and processed for
BrdUrd or PCNA staining.
For studies utilizing ERE-luciferase mice, ovariectomized mice were
injected intraperitoneally with either 50 g/kg E2, vehicle (vegetable
oil), or two injections of 200-g-long R3 IGF-1 in 200 l vegetable oil,
with the second injection of IGF-1 given 3 h after the first injection.
Uteri were collected 6 h after injection with E2 or vehicle or 3 h
following the second IGF-1 injection.
IGF-1R Immunoprecipitation—IGF-1 signaling components were an-
alyzed by immunoprecipitation and Western blot procedures as previ-
ously described (7). In brief, frozen samples of uterine horns were
homogenized at 4 °C in 200 l of solubilization buffer (20 mM HEPES,
2 mM EDTA, 2 mM EGTA, 1% Triton X-100) containing protease and
phosphatase inhibitors (20 g/ml aprotinin, 20 g/ml leupeptin, 4 g/ml
a-phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 20 mM NaF, 0.05 mM
Na2MoO4). Homogenates were normalized for protein concentration
(BCA Protein Assay, Pierce), and equivalent amounts of protein were
pre-cleared by incubation with protein A-Sepharose and then subjected
to immunoprecipitation with 5 g of anti-mouse IGF-1R polyclonal
antibody with an equal volume of 2 immunoprecipitation buffer (100
mM Tris, pH 8.5, 300 mM NaCl, 10 mM EDTA, 1% Triton X-100) for 1 h
at 4 °C. Antigen-antibody complexes were captured with protein A-
Sepharose for 3 h and subjected to three sequential washes (Wash 1:
0.5% Triton X-100, 1 mM EDTA, 500 mM NaCl in 50 mM Tris, pH 8.5;
Wash 2: 0.5% Triton X-100, 1 mM EDTA, 150 mM NaCl in 50 mM Tris,
pH 8.5; Wash 3: 0.1% Triton X-100 in 10 mM Tris, pH 8.5). Precipitated
antigen was eluted from the protein A-Sepharose by resuspending it the
pellets in Laemmli sample buffer and boiling for 5 min.
Immunoblots—Immunoprecipitated proteins or uterine extracts
were resolved by SDS-PAGE and transferred to polyvinylidene difluo-
ride membranes (Millipore, Bedford, MA). Membranes were blocked in
either Tris-buffered saline with 5% bovine serum albumin for detection
of IGF-1R, phosphotyrosine, Akt, phospho-Akt, p42/44 MAPK, phospho-
p42/44 MAPK, and p85, or phosphate-buffered saline with 3% nonfat
dry milk for detection of IRS-1. Membranes with IGF-1R immunopre-
cipitates were probed with anti-phosphotyrosine, anti-IRS-1, anti-p85,
or anti-IGF-1R antibodies. Membranes with total uterine proteins
were probed with anti-Akt, anti-phospho-Akt, anti-p42/44 MAPK,
or anti-phospho p42/44 MAPK antibodies. Enhanced Chemi-
luminescence (ECL, Amersham Pharmacia Biosciences) was used for
detection of immunoreactive proteins according to the manufacturer’s
specifications.
Immunohistochemistry—Immunohistochemical staining of PCNA
was performed as described previously (7). The primary antibody used
was anti-mouse PCNA 19A2 (Beckman Coulter), and the secondary
antibody used was biotinylated anti-mouse IgM (Vector Laboratories).
ExtrAvidin peroxidase (Sigma) was added and detected with the No-
vaRed detection system (Vector Laboratories) according to the manu-
facturer’s instructions. BrdUrd was detected using the BrdUrd staining
kit from Oncogene (Boston, MA) according to the manufacturer’s in-
structions. Immunohistochemistry for luciferase was performed as de-
scribed previously (11). The primary antibody used was a polyclonal
anti-luciferase antibody (Sigma, 1:1800 dilution in phosphate-buffered
saline with 10% goat serum and 0.3% Tween 20) for 16 h; an anti-rabbit
secondary antibody (1:200 dilution in phosphate-buffered saline with
1% goat serum and 0.3% Tween 20) was also used. Antibody-antigen
detection was performed with the ABC kit (Vector Laboratories) accord-
ing to manufacturer’s specifications. Immunostaining was visualized by
exposure to 3,3-diaminobenzidine.
Luciferase Assays—Assays for uterine luciferase activity were per-
formed as described previously (11). Briefly, uterine extracts were pre-
pared by homogenization in 500 l of 100 mM KPO4 lysis buffer (pH 7.8)
containing 1 mM dithiothreitol, 4 mM EGTA, 4 mM EDTA, 0.7 mM
phenylmethylsulfonyl fluoride followed by three cycles of freezing-
thawing and 30 min of microcentrifugation at maximum speed. Super-
natants containing luciferase were collected, and the protein concen-
tration was determined by Bradford’s assay. Luciferase enzymatic
activity in tissue extracts was measured by a commercially available kit
(Luciferase Assay System, Promega, Madison, WI) according to the
manufacturer’s instructions. The light intensity was measured with a
luminometer (Lumat LB 9501/16, Berthold) over 10 s and was ex-
pressed initially as relative light units over 10 s/g proteins.
Statistical Analysis—Luciferase activities were analyzed by analy-
sis-of-variance followed by post hoc analyses with the Scheffe´ test.
RESULTS
Analysis of Estrogen- and IGF-1-stimulated Uterine DNA
Synthesis and PCNA Expression—One indication of estrogen
activity is the wave of DNA synthesis and mitosis that occurs in
the uterine epithelium following administration of hormone.
[3H]thymidine incorporation has been shown to increase to a
maximal level at 16 h following E2 treatment of ovariecto-
mized mice (12). Previous studies indicated that this estrogen-
dependent response is negligible in the ERKO mouse (13). To
determine whether IGF-1 can initiate a similar DNA synthesis
response in the ERKO uterus as well as to identify the specific
uterine cell types that respond to IGF-1, immunohistochemical
analysis of BrdUrd incorporation was performed. As expected,
E2 treatment of WT animals resulted in extensive BrdUrd
incorporation in the luminal and glandular epithelium (Fig.
1A) 16 h following hormone treatment. Long R3 IGF-1 infusion
also resulted in positive BrdUrd immunoreactivity in epithelial
cells. However, the response was decreased compared with that
of the E2 treatment group (Fig. 1A). This confirms that IGF-1
signaling initiates an estrogen-like DNA synthesis response in
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the uterine epithelium and that the response to this particular
method of long R3 IGF-1 treatment is less extensive than the
response to E2. Uteri from ERKO mice revealed no BrdUrd
staining at 16 h following exposure to E2 or long R3 IGF-1 (Fig.
1A), indicating that DNA synthesis is not induced by either E2
or IGF-1 pathways in the absence of ER.
Adjacent tissue sections from WT and ERKO uteri were
also stained with antibody for PCNA as a marker for cell
proliferation. As with the BrdUrd staining, both E2 and long R3
IGF-1 induced an increase in PCNA immunoreactivity in the
WT uterus, whereas neither E2 nor long R3 IGF-1 treatment
resulted in increased PCNA staining in the ERKO uterus
(Fig. 1B). These results suggest that ER is an integral com-
ponent in the IGF-1-stimulated uterine epithelial proliferative
response. When WT mice were given long R3 IGF-1 together
with E2, the response did not appear to be increased compared
with E2 alone (data not shown), suggesting that both of these
stimuli exert their effects on DNA synthesis and PCNA expres-
sion through a common pathway.
The DNA synthesis observed in the wild-type uterus follow-
ing IGF-1 infusion is less robust than that observed in response
to E2, suggesting that ER may not have full transcriptional
activity in the absence of estrogen ligand. Although this finding
is in agreement with in vitro data showing that ERE-driven
reporter and endogenous genes are not as responsive to IGF-1
as to E2 (9, 34), it should also be considered that the peak time
for DNA synthesis after IGF-1 exposure may be decreased
compared with the peak time for DNA synthesis following
exposure to E2.
Proximal IGF-1R Signaling Is Preserved in the ERKO Uter-
us—To eliminate the possibility that dysfunctional IGF-1R sig-
naling was the basis for the lack of IGF-1-induced DNA syn-
thesis and PCNA expression in the ERKO uterus,
ovariectomized mice were treated with E2 or infused with long
R3 IGF-1, and uterine extracts were isolated and analyzed for
IGF-1-stimulated responses. Because E2-stimulated IGF-1 pro-
duction is an induced response that occurs for only a fixed
amount of time (14), phosphorylation of IGF-1R can only be
measured from 3–6 h after exposure to E2 (3). Therefore, for
this set of experiments extracts from E2-treated animals were
prepared 6 h after injection with E2, whereas IGF-1-treated
uteri were prepared 16 h after continuous infusion of long R3
IGF-1. Following long R3 IGF-1 treatment and in agreement
with previously published data (7), uterine IGF-1R was ty-
rosine-phosphorylated in ERKO mice, confirming that the
delivery of long R3 IGF-1 was effective and that the IGF-1R in
the ERKO uterus was responsive to IGF-1 (Fig. 2A). Also as
previously described, treatment with long R3 IGF-1 increased
the formation of an IGF-1R signaling complex comprising IGF-
1R, IRS-1, and p85 ((Refs. 3 and 4, Fig. 2B). Furthermore, after
long R3 IGF-1 treatment, the IRS-1 associated with IGF-1R
was tyrosine-phosphorylated (Fig. 2A). None of these responses
occurred in the ERKO uterus after treatment with E2 (Fig. 2,
A and B). In wild-type mice IGF-1R activation and recruitment
of IRS-1 and p85 occur in response to either E2 or long R3 IGF-1
infusion (data not shown; Ref. 7), confirming that in this mouse
model either E2 or IGF can induce IGF-1R activation.
The p85 component associated with the IGF-1R complex is
the regulatory subunit of PI 3-kinase, and the PI 3-kinase
substrate Akt is phosphorylated and activated in response to
IGF-1 by this pathway (10, 15). To further characterize the
downstream IGF-1R signaling events in the ERKO, uterine
Akt phosphorylation was monitored after treatment with E2 or
long R3 IGF-1. As shown in Fig. 3A, E2 treatment increased
phosphorylation of Akt on Ser 473 in the WT but not the
ERKO uterus, whereas IGF-1 treatment stimulated uterine
Akt phosphorylation in both genotypes. This indicates that
activation of the PI 3-kinase pathway by IGF-1 can occur in the
ERKO but that E2-initiated Akt activation requires the pres-
ence of functional ER. Taken together these data (Figs. 2 and
FIG. 1. Uterine BrdUrd and PCNA immunohistochemistry af-
ter E2 or IGF-1 treatment. 16 h after treatment with vehicle (VEH),
E2, or IGF-1, tissues were prepared as described under “Experimental
Procedures” and stained for BrdUrd (A, dark brown/black staining) or
PCNA (B, dark red staining). In each case, the left panels represent WT
uteri, and the right panels represent ERKO uteri. The arrows point to
immunoreactive epithelial cells. Each treatment group contained three
or four mice, and the panels shown are representative of two separate
experiments. ERKO uteri were photographed at a higher magnifica-
tion (40) than the WT uteri (20) to better present the absence of
immunoreactivity in the ERKO uteri.
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3A) demonstrate that the ERKO uterus is fully responsive to
IGF-1 with respect to activation of signaling events proximal to
IGF-1R.
Mitogen-activated protein kinase (MAPK) has been shown to
be activated by E2 in vitro (16, 17), and activation of MAPK by
IGF-1 has also been demonstrated in vitro in hormone-respon-
sive cells (18). In addition, phosphorylation of ER by MAPK has
been reported (19, 20). In WT uteri IGF-1 increased the phos-
phorylation of uterine p44/42 MAPK (Fig. 3B). In the ERKO
uteri IGF-1 also increased p44/42 MAPK phosphorylation, in-
dicating that ER is not required for MAPK activation by
IGF-1 in the uterus. A basal level of p44/42 MAPK phospho-
rylation was observed in the control groups of both genotypes
(Fig. 3B). Phosphorylation of MAPK by E2 above basal levels
did not occur in the majority of the WT samples; however, the
results varied, possibly because of a suboptimal sampling time
for this response after E2 treatment, and further investigation
is necessary to determine the effects of E2 on MAPK activity in
vivo. MAPK was not activated above basal levels by E2 in any
of the ERKO uterine samples.
IGF-1 Stimulates ER Transactivation in Vivo—The data
described in the preceding sections demonstrate that IGF-1
alone can not reproduce E2-induced effects and indicate that
ER plays an active role in IGF-1-induced proliferative re-
sponses in the uterus rather than simply a permissive role
through induction of IGF-1 synthesis. To determine whether
long R3 IGF-1 can activate ER in vivo, ovariectomized adult
ERE-luciferase mice were treated with E2 or long R3 IGF-1.
Based on the initial data described for these mice (11), uteri
were removed and assayed for luciferase activity 6 h following
injection of E2. Additionally, a pilot study demonstrated that
3 h after injection of IGF-1 in oil, uterine IGF-1R was tyrosine-
phosphorylated; 6 h after injection uterine IGF-1R was still
tyrosine-phosphorylated, although to a lesser extent (data not
shown). Therefore, giving two successive injections of long R3
IGF-1, 3 h apart, was chosen as the course for administering
IGF-1 for these experiments. Treatment with E2 stimulated
approximately an 8-fold increase in the amount of uterine
luciferase activity compared with vehicle-treated controls.
Treatment with long R3 IGF-1 increased the amount of lucif-
erase activity by6-fold above vehicle-treated controls (Fig. 4).
To verify that in this model system the IGF-1 was indeed
inducing luciferase expression through an ER-dependent
mechanism, mice were simultaneously treated with long R3
IGF-1 and the ER antagonist ICI 182,780. Cotreatment with
ICI 182,780 abrogated the induction of luciferase activity that
was observed in response to both E2 and long R3 IGF-1 (Fig. 4).
As a control for both E2 and IGF-1 activity, livers from treated
mice were also sampled and assayed for luciferase activity.
Both E2 and IGF-1 stimulated luciferase activity in liver, and
ICI inhibited this stimulation (data not shown).
It is noteworthy that the IGF-1-induced activation of ER-
mediated transcription measured in the ERE-luciferase mouse
FIG. 2. Proximal uterine IGF-1R signaling is functional in the
ERKO mouse uterus. Six h after treatment with vehicle (VEH) or E2
or 16 h after treatment with long R3 IGF-1, uterine homogenates were
prepared, and IGF-1R was immunoprecipitated as described under
“Experimental Procedures” and analyzed by immunoblotting for phos-
photyrosine (pY), IRS-1, p85, and IGF-1R. Each lane contains a sample
from a single uterus and is representative of uteri from at least 3
separate experiments where a treatment group consisted of no less than
3 animals. A, IGF-1 R immunoprecipitates immunoblotted and probed
with anti-pY antibody. B, IGF-1R immunoprecipitates were immuno-
blotted and probed with antibodies to IRS-1, p85, or IGF-1R proteins.
FIG. 3. Activation of uterine Akt by E2 or IGF-1. Six h after
treatment with vehicle (VEH) or E2 or 16 h after treatment with IGF-1
(IGF), uterine extracts were analyzed by immunoblotting using anti-
bodies to Akt or phosphoserine 473 Akt (pSer473-Akt) (A) or to p44/p42
MAPK or phosphorylated p44/p42 MAPK (B). Each lane represents a
single animal and no less than 3 animals/treatment group.
FIG. 4. IGF-1-induced activation of uterine ERE-luciferase ac-
tivity. Six h after treatment with vehicle (VEH), E2, IGF-1 (IGF), E2 
ICI 182,780 (ICI), or IGF  ICI, tissue extracts were prepared and
assayed for luciferase activity as described under “Experimental Pro-
cedures.” Each bar is the average of at least 6 individual animals. Error
bars represent standard deviation. *, p  0.01 compared with vehicle;
, p  0.01 compared with E2; E, p  0.01 compared with IGF-1. The
numbers given above each bar indicate the average fold-induction above
vehicle.
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was comparable with that observed in response to E2, unlike
the stimulation of DNA synthesis, which may suggest that in
this case ER was fully activated. However, it should be recog-
nized that treatment of ovariectomized mice with E2 or IGF-1 is
a form of pharmacological manipulation, and both experiments
administered IGF-1 in separate ways and at different concen-
trations. In addition, the luciferase response measures a single
reporter gene that has been engineered for maximal induction
by ER and is not comparable with the mitotic response, which
is the result of modulation of many necessary components and
might have varying sensitivity to the growth factor activated
ER. Therefore, differences between local concentrations of E2
and IGF-1 that may arise from endogenous versus exogenous
hormone sources, methods of administration, and differences in
the measured response preclude any firm conclusions being
drawn with respect to the potency of E2 compared with IGF-1
in the activation of ER and downstream events.
The incorporation of BrdUrd and elevated expression of
PCNA in response to IGF-1 were observed only in the uterine
epithelium (Fig. 1). To identify which cells within the uterus
were responding to long R3 IGF-1 by inducing ER/ERE-driven
luciferase expression, immunohistochemical localization of lu-
ciferase was performed. In agreement with the stimulation of
DNA synthesis and expression of PCNA, long R3 IGF-1 induced
expression of luciferase in the epithelial cells of the uterus
(Fig. 5).
To confirm that the long R3 IGF-1 treatment was activating
signaling components of the IGF-1 pathway and, importantly,
that ICI was not interfering with that activation, separate
sections of the same uteri used in the above experiment were
examined as described earlier. As expected, both E2 and IGF-1
stimulated IGF-1R and Akt phosphorylation (Fig. 6, A and B),
confirming that IGF-1 signaling proximal to the IGF-1R was
activated. At this 6-h time point, only residual IGF-1R phos-
phorylation in response to E2 could be observed. In the pres-
ence of ICI 182,780 IGF-1 also induced the activation of IGF-1R
and AKT (Fig. 6, A and B), demonstrating that inhibition of
IGF-1-stimulated luciferase activity by ICI 182,780 was medi-
ated through ER antagonism and was not a result of interfer-
ence between ICI 182,780 and proximal IGF-1 signaling events.
ICI inhibited E2-induced activation of IGF-1R, presumably
through inhibition of IGF-1 gene expression. Interestingly, ICI
did not inhibit E2-stimulated Akt activity, indicating that E2
may activate Akt through more than one mechanism, at least
one of which may be IGF-1-independent and perhaps another
of which is not affected by ICI inhibition of ER. The apparent
increase in IGF-1R phosphorylation in the uteri of mice co-
treated with IGF-1 and ICI, compared with IGF-1 alone, is
most likely because of increased immunoprecipitation of
IGF-1R and interanimal variation in the particular sample
presented here (Fig. 6 A, lower panel).
DISCUSSION
Growth factors such as EGF and IGF-1 are believed to be an
integral component in the growth response of the rodent uterus
to E2. Expression of EGF and IGF-1 as well as IGF-1R signal-
ing can be induced by E2 (21–24), suggesting that these growth
factors may play a fundamental role in mediating the uterine
response to E2. Studies utilizing the IGF-1 knockout mouse
model have shown that although DNA synthesis occurs in the
uterine epithelium in response to E2, there is a significant
decrease in mitotic index after E2 treatment, indicating that
estrogen must induce IGF-1 expression for a full uterine mi-
totic response to occur (6). It is unknown, however, whether
IGF-1 replacement would rescue normal mitosis in this model.
A transgenic mouse that overexpresses IGFBP-1, resulting in
lower serum IGF-1 levels, and possibly lower levels of locally
produced IGF-1 in the uterus, was also shown to have an
impaired uterine response to E2 (26). Both the thymidine in-
FIG. 5. Immunolocalization of E2 and IGF-1-induced luciferase
expression. Six h after treatment with vehicle (VEH), E2, IGF-1, or
IGF-1 ICI 182,780 (IGF-1 ICI), uterine sections were prepared, and
immunolocalization of luciferase was performed as described under
“Experimental Procedures.” Each section is representative of at least 4
animals/treatment group.
FIG. 6. Activation of IGF-1R signaling in ERE-luciferase mice.
Six h after treatment with vehicle (VEH), E2, IGF-1, E2  ICI 182,780
(ICI), or IGF-1  ICI, uterine homogenates were prepared and IGF-1R
immunoprecipitations were performed as described under “Experimen-
tal Procedures” and analyzed by immunoblotting for phosphotyrosine
(pY) and IGF-1R. Additionally, tissue extract was immunoblotted and
probed with antibodies for Akt and phosphoserine 473 Akt (pSer473-
Akt). Each lane is a sample from an individual animal and is represent-
ative of at least 4 animals/treatment.
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corporation and uterine weight increases that occur in response
to E2 were blunted in IGFBP-1-overexpressing mice compared
with nontransgenic mice. Although both of these studies un-
derscore the importance of IGF-1 for a complete uterine re-
sponse to E2, they provide no information about the specific role
of IGF-1 in mediating the uterotropic effects of E2.
The ERKO mouse provides an appropriate model for the
expansion of parallel studies of the converse role of ER in
growth factor action to an in vivo system. Previous studies from
our laboratory demonstrated that treatment with EGF alone
stimulated an increase in [3H]thymidine incorporation in the
wild-type but not in the ERKO mouse uterus, providing in
vivo evidence that ER is necessary for growth factor-induced
uterine DNA synthesis (32). In the present study we demon-
strate that both IGF-1 and E2 are capable of eliciting prolifer-
ative responses in the uterus. Furthermore, the data establish
that ER is required for a proper response to either stimulus
and that the IGF-1 and ER pathways have separate yet in-
teracting functions.
In cell culture models with defined and controlled compo-
nents, both EGF and IGF-1 have been shown to stimulate
ER-mediated responses independent of E2 (8, 9, 27–31). These
studies described the ability of growth factors to activate ER(),
allowing for the hypothesis that one role of the growth factors
in the normal physiologic response of the uterus to E2 may be
the amplification of ER signaling whereby signaling through
growth factor membrane receptors may result in further or
more persistent activation of ER. The recent generation of the
ERE-luciferase mouse model has provided a unique tool for
examining the physiological activity of estrogen receptors in
vivo. By using this model system in the present study, we are
able to report the novel observation that, in agreement with the
previously described in vitro studies, IGF-1 can indeed activate
ER-mediated transcription of a target gene in vivo. This trans-
genic mouse should provide a wealth of information regarding
the role of growth factor signaling pathways in ligand-inde-
pendent activation of ER as well as provide a model system for
the dissection of the molecular mechanisms involved the acti-
vation of ER by growth factors.
The identification of Akt as an integral component in the
mechanism of ER activation by IGF-1 is described in a recent
report demonstrating that Akt is activated by IGF-1 and is
required for stimulation of ER functions in MCF-7 cells and
COS-1 cells (10). An additional study described the role of PI
3-kinase in ligand-independent activation of ER, providing
data suggesting that PI 3-kinase activates ER through both
Akt-dependent and -independent mechanisms (33). The failure
of DNA synthesis to occur in the ERKO uterus even after full
activation of proximal IGF-1R signaling by IGF-1, including
Akt activation, suggests that the requirement of ER for the
mechanism to progress may be as a target for Akt, as the recent
in vitro study indicates (10). The data herein do not demon-
strate activation of MAPK by E2; however, the time after E2
exposure at which MAPK activation was measured may not be
optimal. Previous in vitro studies demonstrated that activation
of MAPK by E2 occurred in a rapid fashion and returned to
basal levels within 1 h after exposure (16, 17). Based on the
results reported here that demonstrate the increased activa-
tion of uterine MAPK in response to IGF-1 in both the wild-
type and ERKO uterus, a requirement for the MAPK signal-
ing pathway in the activation of ER by IGF-1 has not been
ruled out.
Estrogen is a potent mitogen in the mouse uterus, and pre-
vious studies with the ERKO have shown that ER is essen-
tial for hormone-initiated proliferation (7, 13). In the present
study, it is apparent that the role of ER in this mechanism is
not merely to induce growth factors such as IGF-1, which then
lead to proliferative responses. IGF-1 infusion does not restore
uterine responses in the absence of ER even in the presence of
a functional IGF-1 signaling cascade, underscoring the impor-
tance of ER as an active mediator of IGF-1 and possibly other
growth factor proliferative actions in the uterus. Furthermore,
we provide novel evidence that IGF-1/ER cross-talk occurs in
vivo by demonstrating that IGF-1 alone can activate ER-medi-
FIG. 7. Schematic diagram of proposed model for IGF1/ER cross-talk in the uterus. E2 can activate ER directly through the classical
E2/ER binding mechanism (solid red line arrow and red oval). Alternatively, these data, along with previously reported in vitro data, demonstrate
that IGF-1 can also activate ER (solid blue line arrow and blue oval), possibly through a mechanism involving PI 3-kinase/Akt and/or MAPK
(broken line arrow). Either mechanism of ER activation appears to be sufficient to elicit a DNA synthesis response and expression of the
proliferative markers (PCNA). Activation of ER appears to be the crucial molecular event for this response as in the ERKO uterus IGF-1-induced
DNA synthesis does not occur in the absence of ER. It remains to be determined whether ER activation by either pathway alone is sufficient for
a full estrogenic response or whether concomitant activation of ER by both pathways (purple oval) is necessary.
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ated transcription in the mouse uterus. Based on the data
presented, we hypothesize that uterine DNA synthesis can be
initiated by activation of ER either directly by binding E2 or
indirectly by IGF-1R pathway-mediated activation of ER (Fig.
7). When E2 does not induce IGF-1 ligand, as in the IGF-1
knockout, ER can still be activated directly by E2 and DNA
synthesis occurs. In the ERKO not only is IGF-1 induction in
response to E2 disrupted but also ER is not present as a target
of either E2 binding or IGF-1R signaling; therefore, neither
molecule can induce DNA synthesis. These observations, com-
bined with those reported here in the ERE-luciferase mouse,
demonstrating in vivo activation of ER by IGF-1, illustrate the
role of ER as a target for both E2 and IGF-1 and suggest that
ER activation by either mechanism is essential for a uterine
proliferative response to occur.
With respect to the relevance of these findings to normal in
vivo physiology, it is important to consider the role of IGF-1 in
disease. In light of the present findings demonstrating that
IGF-1 can activate ER transactivation functions in the absence
of E2, it may be worthwhile to consider that IGF-1 and perhaps
other growth factors may affect endocrine-related cancers, even
in the absence of steroid hormones, by circumventing the need
for the hormone to elicit a proliferative response in target cells.
It will, therefore, be both interesting and important to compare
the gene expression profiles elicited by IGF-1 and E2 to deter-
mine whether IGF-1 induces unique genes or is simply one
mediator of E2-stimulated gene expression. Additionally, a
comparison of IGF-1 activation of genes regulated by ER
through EREs to those regulated by ER through AP-1 sites will
be informative with respect to the role of IGF-1, and potentially
other growth factors, in the activation of ER-mediated gene
expression. All three model systems mentioned here, the IGF-
1KO, the ERKO, and the ERE-luciferase mice, can be out-
standing tools for comparisons that will help broaden our un-
derstanding of the role(s) of IGF-1 in E2-induced responses in
target tissues in the context of both normal and neoplastic
conditions.
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